Our results suggest that RORα activators could provide a good strategy for the development of effective therapeutics for liver diseases mediated by the IL-6Rα–STAT3 axis, such as hepatic injury with APR and hepatocellular carcinoma. This evidence concerns the gene IL6R and liver disorder.